RecruitingPhase 1NCT07408089
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)
Sponsor
Boundless Bio, Inc.
Enrollment
96 participants
Start Date
Feb 25, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- Adults with locally advanced or metastatic breast cancer, including estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) disease or triple-negative breast cancer with luminal androgen receptor subtype (TNBC-LAR; androgen receptor expression ≥10% by immunohistochemistry), as applicable by study part.
- Prior treatment with standard therapies known to provide clinical benefit, appropriate for disease subtype and study part, including endocrine therapy with CDK4/6 inhibition for ER+/HER2- disease.
- Measurable disease per RECIST v1.1, except for participants enrolled in Part 1A.
- Molecular eligibility as applicable by study part, including absence of an ESR1 mutation (Part 2A) or presence of FGFR1 amplification (Part 2B), based on prior local testing.
- Availability of archival or newly obtained formalin-fixed, paraffin-embedded (FFPE) tumor tissue suitable for protocol-specified biomarker analyses.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate hematologic, hepatic, renal, and coagulation function per protocol-defined laboratory criteria.
- Estimated life expectancy of at least 12 weeks.
- Ability to swallow oral medication and provide written informed consent.
Exclusion Criteria12
- Prior exposure to an inhibitor or degrader of Kinesin.
- Known hypersensitivity to study intervention(s) or excipients.
- Receipt of recent anticancer therapy within protocol-defined washout periods.
- Other active malignancy likely to interfere with study assessment.
- Baseline QTcF \>470 msec or congenital long QT syndrome.
- Clinically significant pulmonary embolism within 6 weeks prior to first dose.
- Major surgery within 4 weeks or minor surgery within 2 weeks prior to first dose.
- Active infection requiring systemic therapy within 2 weeks prior to first dose.
- Pregnant or breastfeeding, or planning conception or gamete donation during the study or required post-treatment period.
- Prior solid organ transplant or allogeneic stem cell transplant with protocol-defined exceptions.
- Failure to recover to CTCAE Grade ≤1 (or baseline) from prior anticancer therapy, with protocol-specified exceptions.
- Any serious or uncontrolled medical, laboratory, or psychiatric condition that could compromise safety or study integrity.
Interventions
DRUGBBI-940
Oral small molecule degrader targeting Kinesin.
DRUGFulvestrant
Selective estrogen receptor degrader administered intramuscularly.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07408089
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations